Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

NCTID	NCT05832684 (View at clinicaltrials.gov)
Description	The purpose of this study was to evaluate the safety and efficacy of ZVS101e administered by subretinal injection in subjects with Bietti's crystalline dystrophy (BCD) and to select the optimal effective dose. (Show More)
Development Status	Active
Indication	Bietti Crystalline Dystrophy
Disease Ontology Term	DOID:0050664
Compound Name	ZVS101e
Compound Description	rAAV2/8-hCYP4V2
Sponsor	Chigenovo Co., Ltd
Funder Type	Network
Recruitment Status	Active not recruiting
Enrollment Count	24
Results Posted	Not Available

Target Gene/Variant	CYP4V2
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Functional gene replacement
Route of Administration	Subretinal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV2/8
Editor Type	none
Dose 1	7.5E10 vg
Dose 2
Dose 3
Dose 4
Dose 5

No.of Trial Sites	3
Locations	China